Virtus Wealth Solutions LLC purchased a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund purchased 73,894 shares of the company’s stock, valued at approximately $9,787,000. Astera Labs makes up approximately 2.3% of Virtus Wealth Solutions LLC’s portfolio, making the stock its 9th largest position.
A number of other institutional investors also recently made changes to their positions in the stock. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of Astera Labs during the fourth quarter valued at approximately $25,000. Steward Partners Investment Advisory LLC boosted its stake in Astera Labs by 99.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 199 shares of the company’s stock valued at $26,000 after purchasing an additional 99 shares in the last quarter. Kestra Investment Management LLC bought a new position in Astera Labs during the 4th quarter valued at $28,000. Geneos Wealth Management Inc. acquired a new position in shares of Astera Labs during the 4th quarter valued at $36,000. Finally, Global Retirement Partners LLC raised its stake in shares of Astera Labs by 3,155.6% in the 4th quarter. Global Retirement Partners LLC now owns 293 shares of the company’s stock worth $39,000 after buying an additional 284 shares in the last quarter. 60.47% of the stock is owned by institutional investors and hedge funds.
Astera Labs Stock Up 2.2 %
ALAB opened at $60.13 on Friday. The firm has a market capitalization of $9.75 billion and a P/E ratio of -34.76. The stock has a fifty day moving average of $73.46 and a 200-day moving average of $90.89. Astera Labs, Inc. has a 12-month low of $36.22 and a 12-month high of $147.39.
Insider Transactions at Astera Labs
In other news, CFO Michael Truett Tate sold 34,474 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $92.07, for a total transaction of $3,174,021.18. Following the transaction, the chief financial officer now directly owns 244,242 shares in the company, valued at $22,487,360.94. The trade was a 12.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Philip Mazzara sold 50,000 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $87.46, for a total transaction of $4,373,000.00. Following the completion of the transaction, the general counsel now directly owns 191,209 shares in the company, valued at $16,723,139.14. This trade represents a 20.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 633,990 shares of company stock valued at $54,235,012 over the last three months.
Analysts Set New Price Targets
Several research analysts recently weighed in on the company. Northland Securities raised Astera Labs from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research note on Tuesday, January 28th. Raymond James assumed coverage on shares of Astera Labs in a research report on Friday, March 14th. They set an “outperform” rating and a $82.00 price objective for the company. Barclays boosted their target price on shares of Astera Labs from $87.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Morgan Stanley reduced their target price on shares of Astera Labs from $142.00 to $114.00 and set an “equal weight” rating for the company in a report on Tuesday, January 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price target on shares of Astera Labs in a report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $112.77.
Read Our Latest Stock Analysis on ALAB
Astera Labs Company Profile
Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.
See Also
- Five stocks we like better than Astera Labs
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- CarMax Pulls Guidance: Shares Falling To Buyable Levels
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Bond ETFs for the Diversified Investor
- What is a Secondary Public Offering? What Investors Need to Know
- Robinhood Strategies Could Be a Game-Changer for Young Investors
Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB – Free Report).
Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.